Literature DB >> 27640624

Interleukin-33 in health and disease.

Foo Yew Liew1,2, Jean-Philippe Girard3, Heth Roderick Turnquist4.   

Abstract

Interleukin-33 (IL-33) - a member of the IL-1 family - was originally described as an inducer of type 2 immune responses, activating T helper 2 (TH2) cells and mast cells. Now, evidence is accumulating that IL-33 also potently stimulates group 2 innate lymphoid cells (ILC2s), regulatory T (Treg) cells, TH1 cells, CD8+ T cells and natural killer (NK) cells. This pleiotropic nature is reflected in the role of IL-33 in tissue and metabolic homeostasis, infection, inflammation, cancer and diseases of the central nervous system. In this Review, we highlight the molecular and cellular characteristics of IL-33, together with its major role in health and disease and the potential therapeutic implications of these findings in humans.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27640624     DOI： 10.1038/nri.2016.95

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


  187 in total

Review 1.  Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.

Authors:  Cameron McDonald-Hyman; Laurence A Turka; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2015-03-25       Impact factor: 17.956

2.  Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain.

Authors:  Mélanie Pichery; Emilie Mirey; Pascale Mercier; Emma Lefrancais; Arnaud Dujardin; Nathalie Ortega; Jean-Philippe Girard
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

3.  T1/ST2 promotes T helper 2 cell activation and polyfunctionality in bronchopulmonary mycosis.

Authors:  D Piehler; A Grahnert; M Eschke; T Richter; G Köhler; W Stenzel; G Alber
Journal:  Mucosal Immunol       Date:  2012-09-19       Impact factor: 7.313

4.  Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice.

Authors:  Koubun Yasuda; Taichiro Muto; Tatsukata Kawagoe; Makoto Matsumoto; Yuki Sasaki; Kazufumi Matsushita; Yuko Taki; Shizue Futatsugi-Yumikura; Hiroko Tsutsui; Ken J Ishii; Tomohiro Yoshimoto; Shizuo Akira; Kenji Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-13       Impact factor: 11.205

5.  IL-33 activates tumor stroma to promote intestinal polyposis.

Authors:  Rebecca L Maywald; Stephanie K Doerner; Luca Pastorelli; Carlo De Salvo; Susan M Benton; Emily P Dawson; Denise G Lanza; Nathan A Berger; Sanford D Markowitz; Heinz-Josef Lenz; Joseph H Nadeau; Theresa T Pizarro; Jason D Heaney
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

6.  Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation.

Authors:  Axel M Küchler; Jürgen Pollheimer; Johanna Balogh; Jon Sponheim; Linda Manley; Dag R Sorensen; Paula M De Angelis; Helge Scott; Guttorm Haraldsen
Journal:  Am J Pathol       Date:  2008-09-11       Impact factor: 4.307

7.  Structural insights into the interaction of IL-33 with its receptors.

Authors:  Xi Liu; Michal Hammel; Yanfeng He; John A Tainer; U-Ser Jeng; Linqi Zhang; Shuying Wang; Xinquan Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

8.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03

9.  Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology.

Authors:  G Walzl; S Matthews; S Kendall; J C Gutierrez-Ramos; A J Coyle; P J Openshaw; T Hussell
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307

10.  A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis.

Authors:  Maryam Salimi; Jillian L Barlow; Sean P Saunders; Luzheng Xue; Danuta Gutowska-Owsiak; Xinwen Wang; Li-Chieh Huang; David Johnson; Seth T Scanlon; Andrew N J McKenzie; Padraic G Fallon; Graham S Ogg
Journal:  J Exp Med       Date:  2013-12-09       Impact factor: 14.307
View more
  337 in total

Review 1.  Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.

Authors:  Mark Rusznak; R Stokes Peebles
Journal:  Curr Opin Allergy Clin Immunol       Date:  2019-02

Review 2.  The immunopathology of lung fibrosis: amphiregulin-producing pathogenic memory T helper-2 cells control the airway fibrotic responses by inducing eosinophils to secrete osteopontin.

Authors:  Kiyoshi Hirahara; Ami Aoki; Yuki Morimoto; Masahiro Kiuchi; Mikiko Okano; Toshinori Nakayama
Journal:  Semin Immunopathol       Date:  2019-04-09       Impact factor: 9.623

Review 3.  Cytokines and costimulation in acute graft-versus-host disease.

Authors:  Geoffrey R Hill; Motoko Koyama
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

4.  Inhibitors of class I histone deacetylases attenuate thioacetamide-induced liver fibrosis in mice by suppressing hepatic type 2 inflammation.

Authors:  Zhixuan Loh; Rebecca L Fitzsimmons; Robert C Reid; Divya Ramnath; Andrew Clouston; Praveer K Gupta; Katharine M Irvine; Elizabeth E Powell; Kate Schroder; Jennifer L Stow; Matthew J Sweet; David P Fairlie; Abishek Iyer
Journal:  Br J Pharmacol       Date:  2019-08-17       Impact factor: 8.739

5.  Involvement of the Negative Feedback of IL-33 Signaling in the Anti-Inflammatory Effect of Electro-acupuncture on Allergic Contact Dermatitis via Targeting MicroRNA-155 in Mast Cells.

Authors:  Zhigang Wang; Tao Yi; Man Long; Fengmin Ding; Lichen Ouyang; Zebin Chen
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

6.  A network map of IL-33 signaling pathway.

Authors:  Sneha M Pinto; Yashwanth Subbannayya; D A B Rex; Rajesh Raju; Oishi Chatterjee; Jayshree Advani; Aneesha Radhakrishnan; T S Keshava Prasad; Mohan R Wani; Akhilesh Pandey
Journal:  J Cell Commun Signal       Date:  2018-04-28       Impact factor: 5.782

7.  Interleukin-33 drives hepatic fibrosis through activation of hepatic stellate cells.

Authors:  Zhongming Tan; Qianghui Liu; Runqiu Jiang; Long Lv; Siamak S Shoto; Isabelle Maillet; Valerie Quesniaux; Junwei Tang; Wenjie Zhang; Beicheng Sun; Bernhard Ryffel
Journal:  Cell Mol Immunol       Date:  2017-02-13       Impact factor: 11.530

Review 8.  IL-33/ST2 Axis in Organ Fibrosis.

Authors:  Ourania S Kotsiou; Konstantinos I Gourgoulianis; Sotirios G Zarogiannis
Journal:  Front Immunol       Date:  2018-10-24       Impact factor: 7.561

9.  Toll-Interacting Protein, Tollip, Inhibits IL-13-Mediated Pulmonary Eosinophilic Inflammation in Mice.

Authors:  Yoko Ito; Niccolette Schaefer; Amelia Sanchez; David Francisco; Rafeul Alam; Richard J Martin; Julie G Ledford; Connor Stevenson; Di Jiang; Liwu Li; Monica Kraft; Hong Wei Chu
Journal:  J Innate Immun       Date:  2018-01-27       Impact factor: 7.349

10.  Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33.

Authors:  T Mahlakõiv; A-L Flamar; L K Johnston; S Moriyama; G G Putzel; P J Bryce; D Artis
Journal:  Sci Immunol       Date:  2019-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.